Merus reports 63% confirmed ORR from Phase 2 petosemtamab + pembrolizumab trial

Merus N.V.

In 43 evaluable patients: 63% ORR (6 complete, 21 partial responses) across PD-L1 levels.
Median PFS 9 months (95% CI 5.2-12.9); median DOR and OS not reached; 79% 12-month OS rate.
Combination well tolerated; G≥3 TEAEs in 60% (44% related), infusion reactions 38% (all grades).
Responses seen in 4 of 8 patients with HPV-associated cancer; 73% ORR in PD-L1 CPS>20.
Top-line results from one or both Phase 3 trials expected in 2026.

item 8.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.